Pre-Clinical Screening Program

Preclinical Screening Program

When ABC2 was launched in 2001, one of the most critical In 2002, Accelerate Brain Cancer Cure and the Preston Robert Tisch Brain Tumor Center at Duke University formed the Preclinical Screening Program, a groundbreaking collaboration that establishes a critical missing link between the biopharmaceutical industry’s efforts to produce potentially life-saving drugs and the theoretical knowledge at the cutting edge of scientific inquiry. Funding allows researchers from any sector - academia, industry, and government - to submit compounds that hold the potential to benefit brain cancer research to Duke for screening, free of charge.

This program encourages researchers, corporations, and federal agencies to test both approved and experimental therapies that target other types of cancers for their potential benefit to brain cancer patients. This program is run by an active Executive Committee managed by Accelerate Brain Cancer Cure.

How it Works
Accelerate Brain Cancer Cure and Duke consider requests from drug sponsors for preclinical evaluation. If there is agreement to test the potential therapies, a Material Transfer Agreement (MTA) is created. Once the MTA is signed, testing is initiated. Jointly, Accelerate Brain Cancer Cure and Duke are focused on accountability and maintain frequent interaction during all potential therapy testing.

Impact
To date, more than 150 compounds have been tested or are in under consideration for this program. The researchers at Duke have initiated trials for 18 therapies in brain tumor patients on the basis of results obtained through the Duke Preclinical Testing Program.